Skip to main content

José Antonio Arranz Amo

Institutions of which they are part

Postdoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

José Antonio Arranz Amo

Institutions of which they are part

Postdoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Projects

Enfermedades minoritarias causantes de degeneración de ganglios basales en pedriatría: implemementación combinada del análisis genómico y de biomarcadores.

IP: Perez Dueñas, Belen
Collaborators: José Antonio Arranz Amo, Josefa Élida Vázquez Méndez, Alfons Macaya Ruíz, Clara Carnicer Cáceres, Mireia del Toro Riera, Ana Felipe Rucián
Funding agency: Instituto de Salud Carlos III
Funding: 196020
Reference: PI18/01319
Duration: 01/01/2019 - 31/12/2022

Apolipoproteína AIb como biomarcador y diana terapéutica de la glomeruloesclerosis segmentaria y focal idiopática (GESF)

IP: Joan López Hellin
Collaborators: José Antonio Arranz Amo, Joana Sellarés Roig, Maria Teresa Salcedo Allende, Concepció Jacobs Cachá
Funding agency: Instituto de Salud Carlos III
Funding: 88935
Reference: PI14/00275
Duration: 01/01/2015 - 30/06/2018

Neurodegeneración en la cirrosis hepática: relación con el metabolismo nitrogenado y la inflamación

IP: -
Collaborators: José Antonio Arranz Amo, Xavier Nuvials Casals, Macarena Simon-Talero Horga
Funding agency: Instituto de Salud Carlos III
Funding: 215544.56
Reference: PI11/00954
Duration: 01/01/2012 - 31/03/2016

Efectos de la administración de fenilacetato y ornitina en pacientes con cirrosis hepática que presentan una hemorragia digestiva

IP: -
Collaborators: José Antonio Arranz Amo, Victor Manuel Vargas Blasco, Pilar Suñe Martin
Funding agency: Ministerio Sanidad
Funding: 43962
Reference: TRA-190
Duration: 01/01/2010 - 31/12/2012

Related news

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

During the last year, the collaboration between Vall d’Hebron and ZeClinics has found three nanobody candidates with potent anticancer properties in zebrafish model.

Related professionals

Irene Buera Surribas

Irene Buera Surribas

Cardiovascular Diseases
Read more
María Jurado Ruiz

María Jurado Ruiz

Predoctoral researcher
Reconstructive Surgery of the Locomotor System
Read more
Paula Garcia Rodriguez

Paula Garcia Rodriguez

Research technician
Neurovascular Diseases
Read more
Daniel Alvarez De la Sierra

Daniel Alvarez De la Sierra

Research technician
Translational Immunology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.